Leading healthcare IT analyst firm KLAS today published its inaugural drug diversion monitoring solution report. We are thrilled to announce that Bluesight for Controlled Substances received top marks, earning a rating of 93.2* out of 100!
KLAS’s “Drug Diversion Monitoring 2019, An Early Look at Emerging Vs. Established Technology” highlights hospitals and health systems’ need for drug diversion monitoring technology, and analyzes the solutions with the most significant share of customers in the current market.
KLAS divided the solutions they reviewed into two categories: “Established Solutions” and “Emerging Solutions.” Established tools primarily deal with standard deviation analysis, static reports, and aggregated dispensing data, while Emerging Solutions feature EMR and other system integration, proactive alerts, and data visualization tools. Bluesight for Controlled Substances received an overall performance rating of 93.2% based on customer interviews—nearly 17 points higher than the nearest competitor!
KLAS based its finding on data collected from interviews with customers, industry reports, and websites. The report includes quotes from some of our great hospital staff who use our products every day, and we couldn’t be more proud and grateful for the fantastic feedback. Our customers are our partners, and creating products that keep patients safe while also creating efficiency is what drives everything we do.
* Scores and ratings are based on conditions of low data.